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Abstract 
Platelet-activating factor (PAF), a phospholipid autacoid with potent regulatory functions, is synthesized by stimulated monocytes. 
Macrophages are a source of the plasma cetylhydrolase activity (AHA) which regulates PAF concentrations. Granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are involved in the differentiation and functions 
of cells from the monocytic/macrophagic lineage. This work reports that M-CSF and GM-CSF stimulated AHA production by human 
blood monocyte-derived macrophages in a time- and dose-dependent manner. After 7 days of culture without serum, a 6- and 4-fold 
increase was found in cells treated with M-CSF (1000 U/ml) and GM-CSF (50 ng/ml), respectively. M-CSF (up to 1000 U/ml) and 
GM-CSF (up to 10 ng/ml) did not induce PAF production by human blood monocytes. While GM-CSF (10 ng/ml) and interleukin-1 ( 0 
U/ml) stimulated M-CSF production from monocyte-derived macrophages, PAF did not. These results indicate that M-CSF and GM-CSF 
enhance AHA production by human blood-derived macrophages cultured in low serum concentrations. Clearly the effects of growth 
factors on AHA production in vivo deserve to be assessed. 
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1. Introduction 
Platelet-activating factor (PAF) is a phospholipid com- 
pound produced by most cell types involved in inflamma- 
tion [1]. During the last ,decade numerous tudies have 
shown the immunoregulatory properties of PAF, which 
exhibits potent effects on various blood cell types such as 
T -and  B-lymphocytes, polymorphonuclear neutrophils, 
eosinophils and monocytes/macrophages [2,3]. In human, 
blood PAF levels are regulated by a plasma PAF acetylhy- 
drolase activity (AHA) which cleaves the acetyl group 
from the sn-2 position to convert PAF into inactive lyso 
PAF [4,5]. Monocytes/macrophages play a key role in the 
initiation and the development of immune and inflamma- 
tory PAF-mediated response. Stimulated monocytes re- 
lease a large fraction of their newly synthesized PAF [6] 
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and macrophages are a major source of the plasma AHA 
[7]. PAF metabolism is modified during the differentiation 
of monocytes to macrophages [8]. It is of evidence that the 
balance between PAF and AHA production during the 
differentiation of peripheral blood monocytes to 
macrophages is of pathophysiological importance. 
Macrophage colony-stimulating factor (M-CSF) and granu- 
locyte-macrophage colony-stimulating factor (GM-CSF) 
belong to the family of haematopoietic growth factors that 
regulate the production and several functions of blood 
cells, from bone marrow progenitors to mature circulating 
elements. While GM-CSF acts on bipotential progenitors 
to produce mononuclear phagocytes and granulocytes, M- 
CSF acts specifically on cells of the monocytic lineage 
[9,10]. Thus, these two cytokines are involved in the 
survival, proliferation, differentiation and several functions 
of monocytic cells from progenitors to mature 
macrophages. 
GM-CSF has been reported to be a stimulant of PAF 
generation by human neutrophils [11] and to exhibit prim- 
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ing effects on numerous eosinophil functions including 
PAF production [12]. At this time no such data have been 
reported for monocytes/macrophages. In this study we 
have investigated (1) the effects of M-CSF and GM-CSF 
on the production of AHA, on the synthesis of PAF, and 
the catabolism of PAF by human blood monocyte-derived 
macrophages; and (2) the effect of PAF on the production 
of M-CSF by these cells. 
2. Materials and methods 
2.1. Reagents 
Synthetic PAF (Tebu, France) was dissolved in ethanol 
at a concentration f 10 mM. The solution was evaporated, 
redissolved in RPMI 1640 (Gibco, France) containing 
0.25% human serum albumin (Bio Merieux, France) at a 
concentration f 100 /xM and stored at -20°C until used. 
M-CSF was from Cetus Corporation (Emeryville, CA), 
GM-CSF was from Sandoz (Austria), interleukin 1 was 
from Hoffmann-La Roche (Nutley, NJ). Hanks' balanced 
salts solution (HBSS), penicillin, streptomycin and fetal 
calf serum (FCS) were from Gibco (France). Creatine 
phosphokinase, creatine phosphate, bovine serum albumin 
(BSA), phosphatidylcholine, lyso PAF and 4-fl-phorbol 
12-myristate 13-acetate (PMA) were obtained from Sigma 
(St. Louis, MO). Aspirin lysin salt (Aspegic) was from lab 
Egic (Amilly, France). [3H]Alkyl PAF was from Amer- 
sham (Les Ulis, France) and [3H]acetyl PAF was from 
NEN (Les Ulis, France). 
2.2. Preparation and stimulation of human monocytes 
Peripheral blood mononuclear cells from human volun- 
teers were obtained after two steps of density-gradient 
centrifugation [Ficoll, d = 1.077 at 280 X g for 20 min 
(Eurobio, France) followed by a gradient of Nycodenz ®, 
d= 1.063 at 280Xg for 15 min (J. Bio, France)]. 
Mononuclear cells were resuspended in Ca 2+, Mg2+-free 
HBSS and washed three times at 280 × g for 10 min. The 
platelet contamination was monitored and was less than 
5%. Cells were resuspended in RPMI 1640 supplemented 
with 100 U/ml  penicillin, 100 /zg/ml streptomycin, and 
25 mM HEPES, plated in 24-well plates (Nunc, France) at 
the density of 3 X 10 6 cells/ml/well  and incubated at 
37°C for 12 h in 5% CO 2 in air. The non-adherent cells 
were removed after three washes with HBSS. Adherent 
cells in representative w lls were removed by scraping and 
enumerated. In addition cell viability was always moni- 
tored by Trypan blue exclusion. 
For PAF production, monocytes were cultured (500 /~1 
final volume) at 37°C in 5% CO 2 in air, in RPMI 1640 
supplemented as above with M-CSF (10-1000 U/ml), 
GM-CSF (0.1-10 ng/ml) and PMA (1 /xM) as a positive 
control for PAF production. After 1 h of culture, cells and 
media were ethanol-extracted (80% final) and stored at 
-20°C until PAF assay. 
2.3. Culture and stimulation of monocyte-derived 
macrophages 
Monocytes were cultured in various concentrations of
FCS (0, 1 and 5%) with or without M-CSF (10 to 5000 
U/ml)  or GM-CSF (0.1 to 50 ng/ml) for 1, 2, 5 or 7 days 
at 37°C in 5% CO 2 in air. After the desired time of 
culture, the medium was recovered and stored at -20°C 
until AHA assay. Adherent cells were removed by scrap- 
ing in 0.5 ml of the AHA buffer medium and stored at 
-20°C until assay. In another set of experiments cells 
were stimulated with M-CSF (100 and 1000 U/ml)  and 
GM-CSF (1 and 10 ng/ml) at day 1 and 3 and AHA was 
assessed at day 7. Finally cells were treated with M-CSF 
(1000 and 5000 U/ml)  at day 5 and AHA was assessed at 
day 7. 
In another set of experiments, cells were cultured in 
various concentrations of serum (0, 1 and 5%). PAF (1 
/xM, 10 nM and 0.1 nM), interleukin 1 (10 U/ml)  and 
GM-CSF (1 ng/ml) were added at day 1. After 7 days of 
culture, the medium was recovered and stored at -20°C 
until M-CSF assay. 
To investigate the metabolism of PAF by monocyte-de- 
rived macrophages, cells were cultured for 7 days with 
M-CSF (1000 U/ml)  or GM-CSF (10 ng/ml) in 0 or 1% 
FCS. Cells were washed 3 times, recovered with 0.5 ml 
RPMI 1640 and the catabolism of exogenous [3H]alkyl- 
PAF (0.5 /xCi, 0.05 nmol) complexed to human serum 
albumin (final concentration 2 mg/ml) was investigated 
after 3 h. Incubations were stopped by the addition of 
methanol/chloroform (2:1, v /v)  to the reaction mixture 
and the lipids were extracted by the method of Bligh and 
Dyer [13]. Recovered products included both cell-associ- 
ated components and those present in the medium. Sam- 
ples were dried and stored at -20°C until used. 
2.4. PAF acetylhydrolase assay 
AHA was assayed according to the method of Miwa et 
al. [14] with minor modifications. Briefly 1 X 105 dpm of 
[3H]acetyl-PAF, l0 Ci/mmol, NEN), 0.1 mM PAF, 
HEPES buffer (pH 7.8) in a final volume of 450 /xl, and 
50 /xl of culture supernatant or sonicated cell extract were 
incubated for 15 min at 37°C. The reaction was stopped 
with 100 /zl BSA (10%) and 500 /zl trichloracetic acid 
(20%). Samples were centrifuged (1500X g, 15 min), 
supernatants were mixed with 2.5 ml of scintillation fluid 
(Opti-fluor, Packard, France) and counted in a liquid scin- 
tillation counter (Packard). One unit of AHA is defined as 
1 pmol PAF degraded per min per 5 X 105 cells. The 
variation between duplicates was less than 6%. Data are 
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expressed as mean + S.E.M. units or as a stimulation index 
using the following formula: [number of units of AHA 
produced by stimulated cells/number of units of AHA 
produced by control cells]. 
2.5. PAF assay 
Washed rabbit platelets were prepared as previously 
described [15,16]. Aspirinated platelets (1.6 X 108) in Ty- 
rode's solution (300 /zl) containing 2.5% gelatin and the 
adenosine diphosphate scavenger mixture, creatine phos- 
phate (1 raM) and creatine phosphokinase (10 U/ml )  were 
stirred in an aggregometer (Labintec, France). The aggre- 
gating activity of the samples was measured over the linear 
portion of the calibration curve obtained with 2.5 to 25 pg 
synthetic PAF. Dry samples were recovered in 50 /zl of 
ethanol 60% and 2 /~1 are used for the assay. Thus, the 
sensitivity of the assay enables detection of PAF levels as 
low as 100 pg per sample. 
2.6. M-CSF assay 
M-CSF production was determined by a self-made EIA 
procedure. Briefly a polyclonal anti-human M-CSF anti- 
serum was obtained after rabbit intralymphnode immuniza- 
tion technique [17]. Antibodies were coated on 96-well 
microtiter plates. Standard dilutions of M-CSF (500 to 8 
U/ml )  and samples were transferred into wells and incu- 
bated overnight at 4°C. Plates were washed and anti-M- 
CSF-biotin conjugate was added to all wells and incubated 
overnight at 4°C. Plates were washed and avidine phos- 
phatase (1 /xg/ml) was added to wells and incubated for 1 
h at 37°C. The revelation was performed with para- 
nitrophenyl-phosphate disodium (4 g/ml)  for 15 min at 
37°C. The reaction was blocked by addition of 50 /zl of 
NaOH 10 N to the wells. Color development was mea- 
sured at OD 405 nm. M-CSF levels in samples were 
calculated with respect o the calibration curve obtained 
with standard M-CSF. 
2.7. Catabolism of PAF 
Labeled compounds derived from [3H]alkyl-PAF were 
separated using thin layer chromatography (TLC) plates 
(Silica Gel 60, 20 × 20 cm, 0.25 mm, Merck, France) 
developed in chloroform/methanol/acetic acid/water 
(50:25:8:4, v /v )  [18]. Each lane was divided in areas of 
0.5 cm length which were scraped into vials, mixed with 
scintillation fluid and their radioactivity was measured on 
a Packard liquid scintillation counter. Unlabeled PAF (l-  
O-alkyl-2-acetyl-glycerophosphocholine), lyso PAF (1-O- 
alkyl-2-1yso-glycerophosphocholine), and phosphatidyl- 
choline (PC) (1-O-alkyl-2-acyl-glycerophosphocholine) 
were used as standards and were visualized with iodine 
vapour. 
3. Results 
Isolated blood mononuclear cells were cultured with 
various concentrations of FCS up to 7 days. The mean 
number of adherent cells gradually decreased from 0.9 X 
10 6 to 0.2 × 10 6, 1 × 10 6 to 0.3 × 10 6 and 1.35 X 10 6 to 
0.4 X 106 over 7 days in culture in 0, 1 or 5% FCS, 
respectively. Viability analysis of adherent cells at day 1, 
2, 5 and 7 did not reveal significant differences in the 
various experimental conditions. In our experimental con- 
ditions M-CSF (up to 5000 U/ml)  and GM-CSF (up to 10 
ng/ml)  had no significant effect on the number of adher- 
ent cells after 7 days of culture. GM-CSF (50 ng/ml)  
significantly (P  < 0.05) enhanced by 1.5-fold the cell 
number at day 7 (data not shown). 
The time course of total (intracellular + secreted) AHA 
produced by adherent cells cultured during 7 days is 
shown in Fig. 1. The intracellular AHA is not significantly 
elevated at day 7 as compared with day 1 in the different 
culture conditions (data not shown). Intracellular AHA 
determined atday 7 was not significantly (P  > 0.05) higher 
in 1% FCS (221_ 46 U) or 5% FCS (384_ 33 U) as 
compared to 0% FCS (231 + 90 U). By contrast, there was 
a significant (0.001 < P < 0.05, Mann-Whitney U-test) in- 
crease at day 5 (not shown) and at day 7 of the AHA 
secreted by cells cultured in 1% FCS (1958 __+ 170 U, 
n = 3) or 5% FCS (2502 + 230 U, n = 3) as compared 
with control (362 ___ 94 U, n = 3). 
We investigated the effects of the addition at day 1 of a 
single dose of GM-CSF and M-CSF on AHA production 
by monocyte-derived macrophages after different imes of 
cultures. The stimulation index of AHA production at day 
7 with respect to the concentrations of FCS and/or M-CSF 
or GM-CSF is shown in Fig. 2A and 2B, respectively. The 
400O 
3500 
3000 
2500 
~ 2°0o 
< 
1500 
lOOO 
5oo 
o 
o 
I 
• 0% FCS | 
I - -~  1% FCS & 5% FCS 
I I I I I I I 
1 2 3 4 5 6 7 
Fig. 1. Total AHA (intracellular+ secreted) increases a  human mono- 
cytes differentiate into macrophages. Human monocytes were cultured for 
1-7 days at the indicated FCS concentrations. Meanfl:S.E.M. of 4 
independent experiments in triplicate. A unit of enzymatic a tivity was 
defined as 1 pmol of acetate produced/min/5 X 105 cells. * P < 0.05 as 
compared today 1 values (Mann-Whitney U-test). 
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Fig. 2. Stimulation i dex of AHA production [ umber of units AHA 
produced by stimulated cells/number of units of AHA produced by 
control cells] induced by M-CSF (2A) or GM-CSF (2B) at day 7 as a 
function of FCS concentrations. Mean -t- S.E.M. of 3 independent experi- 
ments in triplicate. * P<0.05, ** P<O.O1, *** P<O.O01 as com- 
pared with control values (Mann-Whitney U-test). 
total AHA production was higher in cells cultured for 7 
days in 0 or 1% FCS with M-CSF (1000 and 5000 U/ml )  
and GM-CSF (10 and 50 ng/ml)  than in untreated cells. 
While similar results were observed after 5 days of culture, 
no effect was found at days 1 and 2 (data not shown). In 
most experiments more than 90% of the AHA was found 
in the culture medium (data not shown). Addition of 
M-CSF or GM-CSF at day 1 and 3 did not significantly 
(P  > 0.05, Mann-Whitney U-test) enhanced AHA produc- 
tion as compared to cells treated at day 1 (data not shown). 
Finally stimulation of cells at day 5 with M-CSF (1000 
U/ml )  did not increase the AHA production assessed at 
day 7 (data not shown). 
In the next set of experiments, macrophages cultured 
for 7 days in 0% FCS were incubated with [3H]alkyl PAF 
for 5 to 180 rain at 37°C before measuring its metabolism 
as described in Section 2. PAF metabolism was 1% at 5 
min, 7% at 20 min, 30% at 60 min and 74% at 180 min 
(mean of 2 independent experiments). At each time point, 
the metabolic products comigrated with lyso PAF, 
phosphatidylcholine and neutral ipids. As reported in Fig. 
3, 7 days of culture with M-CSF (1000 U/ml )  and GM- 
CSF (10 ng/ml )  stimulated the catabolism of the exoge- 
nously added PAF. While 78% of the label migrated with 
PAF in control cells, 32% and 40% were found in M-CSF- 
and GM-CSF-treated cells, respectively. 
Studies have reported that GM-CSF enhanced PAF 
production by human neutrophils in vitro [l 1]. We have 
assessed whether M-CSF and GM-CSF stimulated PAF 
generation from freshly isolated mononuclear cells and 
from 12-h adherent cells. Stimulation with M-CSF (10-  
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Fig. 3. Distribution of label in products after incubation of[3H]alkyl-PAF 
with monocyte-derived macrophages cultured 7 days in 0% FCS with 
M-CSF (1000 U/ml) or GM-CSF (10 ng/ml). PAF, 1-O-alkyl-2-acetyl- 
glycerophosphocboline; LysoPAF, 1-O-alkyl-2-1yso-glycerophosphocho- 
line; PC (phosphatidylcholinc), 1-O-alkyl-2-acyl-glycerophosphocholine, 
NL (neutral lipids) 1-O-alkyl-2-acetyl-glycerol. One representative trac- 
ing of 2 independent experiments in duplicate is shown. 
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Fig. 4. Effect of M-CSF, GM-CSF and PMA on the production of PAF 
by freshly isolated mononuclear cells. Mean + S.E.M. of 3 independent 
expedments in triplicate. " P < 0.05 as compared with control values 
(Mann-Whitney U-test). 
1000 U/ml)  and GM-CSF (0.1-10 ng/ml) did not in- 
crease the PAF production by freshly isolated mononuclear 
cells (Fig. 4) or by 12-h adherent cells (data not shown). 
By contrast, isolated mononuclear cells stimulated with 
PMA (1 tzM) significantly enhanced PAF production as 
compared to controls. Similar results were obtained with 
cells after 12 h of adherence (300 _ 23 pg PAF/well vs 
158 ___ 6 pg PAF, P < 0.05, for PMA-stimulated and con- 
trol cells, respectively). 
In contrast o monocytes, macrophages secrete M-CSF 
in response to inflammatory compounds in vitro [9]. We 
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Fig. 5. Production of M-CSF by day 7 macrophages stimulated with 
PMA, GM-CSF and IL-1 at day 1. Mean+S.E.M. of triplicates amples. 
One representative experiment of two is shown. * P < 0.05 as compared 
with control values (Mann-Whitney U-test). 
have assessed whether PAF may be a stimulant of M-CSF 
synthesis in macrophages. We confirm that PMA (1 /~M), 
GM-CSF (0.1 ng/ml) and IL-1 (10 U/ml)  significantly 
stimulated M-CSF production by day 7 macrophages (Fig. 
5). By contrast PAF (0.1 nM to 1 /~M) was unable to 
stimulate M-CSF production by day 7 macrophages (data 
not shown). 
4. Discussion 
Because the biological effects of PAF are produced at 
very low concentrations (1 nM to 1 pM), the mechanisms 
regulating its concentration are essential [1-3]. Thus, alter- 
ations of PAF and/or AHA generation could result in 
pathological inflammations. Monocytes are one of the 
sources of blood PAF [6] and macrophages are one of the 
sources of plasma AHA [7]. Previous results reported that 
GM-CSF was a stimulant for PAF production in human 
neutrophils and eosinophils [11,12,19]. We have investi- 
gated the effects of M-CSF and GM-CSF on AHA and 
PAF generation during human peripheral blood mononu- 
clear cell differentiation i to macrophages in vitro. 
We observed that the maturation of human peripheral 
blood monocytes to macrophages by adherence is followed 
by an increase of the secretion of AHA. After 7 days of 
culture there is a 10-fold increase of the AHA which fits 
well with a previously reported 11-fold increase [7]. In our 
experimental conditions a single addition of M-CSF or 
GM-CSF stimulates in a dose- and time-dependent man- 
ner the production of AHA by monocyte-derived 
macrophages. It appears that the stimulatory effect of 
M-CSF and GM-CSF on AHA production decreases when 
the percentage of FCS increases in the cultures. Previous 
studies howed that physiological molecules uch as estra- 
diol, interleukin-1 or tumor necrosis factor down-regulate 
AHA secretion in liver cells [20] and human decidual 
macrophages [21]. Cited results reported that lipopolysac- 
charides inhibited AHA secretion by human peripheral 
monocytes/macrophages [22].One of the most important 
findings of the current study is that M-CSF and GM-CSF 
are the two first molecules found to stimulate AHA secre- 
tion from human peripheral blood monocytes/macro- 
phages. It may be objected that this effect is obtained with 
high concentrations of GM-CSF and M-CSF. While GM- 
CSF is not detectable in serum in steady-state conditions, 
the normal range of M-CSF serum concentrations is be- 
tween 50 and 200 U/ml  [9]. Moreover elevated concentra- 
tions of these growth factors are detected in the circulation 
and/or locally during some physiological situations and 
immunological disorders [9,23-26]. Finally growth factor 
concentrations at local sites may be more relevant han 
those in peripheral blood. 
The catabolism of PAF by cells is an effective mean by 
which cells can regulate its level. Results of the present 
study indicate that macrophages derived from blood mono- 
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cytes by adherence metabolize PAF using the deacetyla- 
tion-transacylation pathway. As in human lymphocytes 
[27] or neutrophils [18], the metabolite lyso PAF is reacy- 
lated with a fatty acid at the position 2 of the glycerol 
backbone. In the present study, 7 days of treatment of 
monocyte-derived macrophages with M-CSF or GM-CSF 
stimulate the catabolism of exogenous PAF. The elevated 
levels of the metabolite lyso PAF may be linked to the 
higher AHA produced by treated cells. 
GM-CSF has been reported to stimulate PAF synthesis 
in neutrophils and eosinophils [11,12,19]. In this study we 
observed that M-CSF and GM-CSF are not stimulants for 
PAF production from freshly isolated mononuclear cells. 
By contrast PMA, a stimulant of PAF generation i mono- 
cytes [8], increases PAF production showing the capacity 
of our cells to generate PAF in response to an appropriate 
PAF stimulus. M-CSF is involved in the survival, prolifer- 
ation and function of monocytic ells to mature macrophage 
[9]. Pro-inflammatory molecules uch as IL-1 and GM-CSF 
have been found to increase M-CSF production by mono- 
cyte-derived macrophages. In this study we were unable to 
increase M-CSF production by monocyte-derived 
macrophages in response to PAF. By contrast, PMA, 
GM-CSF and IL-1 increase M-CSF production, confirming 
that these molecules are stimulants for M-CSF generation 
[28,29], and showing the ability of our cells to generate 
M-CSF in response to appropriate stimuli. 
In conclusion, unlike IL-1 and GM-CSF, PAF is not a 
stimulant of M-CSF production by monocyte-derived 
macrophages. M-CSF and GM-CSF are not stimulant of 
PAF production by mononuclear cells. By contrast the two 
latter molecules increase AHA production from blood 
monocyte-derived macrophages. This study demonstrates a 
novel and potentially important mechanism by which tis- 
sue macrophages could down-modulate PAF-mediated in- 
flammatory responses. During inflammatory ailments tim- 
ulated monocytes produce PAF. During their differentia- 
tion to macrophages, they acquire the capacity to secrete 
AHA and to be stimulated by M-CSF and GM-CSF. The 
locally increased production of these two cytokines at 
inflammatory sites stimulates AHA production, which in 
turn might diminish PAF levels, thus decreasing the in- 
flammatory PAF-mediated response. Clearly further stud- 
ies will be required to confirm this hypothesis n vivo. 
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